Hims & Hers Stock Plunges 21.3% in 3 Months: Time to Hold or Exit?

Hims & Hers (HIMS) reported robust Q2 2025 performance with strong top-line growth, a 30.8% increase in subscribers, and expanded operating margins, yet its stock has recently declined 21.3% due to lower Wholesale revenues and a 491 bps gross margin contraction from rising costs. Despite this underperformance and a 12.3% downward revision in 2025 EPS estimates, the company maintains strong FY2025 revenue guidance of $2.3B-$2.4B and a raised EBITDA outlook, driven by strategic expansion into new specialties, international growth (e.g., ZAVA acquisition, Canada), and AI integration. While its 4X forward P/S is elevated relative to peers, HIMS's strong fundamentals and global opportunities underpin a Zacks 'Hold' rating, suggesting retention for existing investors despite recent price weakness.

Analysis

Hims & Hers Health, Inc. (HIMS) presents a dichotomous profile of strong operational momentum against significant recent stock underperformance. The company's shares have declined 21.3% over the past three months, starkly lagging the industry's 1.7% rise and peers like Teladoc and Amwell. This price action appears driven by specific headwinds reported in its Q2 2025 results, namely disappointing Wholesale revenues and a material 491 basis point contraction in gross margin due to rising product costs. Furthermore, analyst estimates for 2025 earnings per share have been revised downward by 12.3% over the past 60 days. However, these negatives are contrasted by robust fundamental growth, including a 30.8% year-over-year increase in subscribers to 2.4 million and a 29.8% rise in monthly online revenue per subscriber to $74. Management has reaffirmed strong full-year 2025 revenue guidance of $2.3-$2.4 billion (56-63% growth) and raised its EBITDA outlook to $295 million-$335 million, signaling confidence. Growth is being fueled by strategic international expansion, evidenced by the acquisition of European platform ZAVA and a planned 2026 entry into Canada's weight-loss market. At a forward price-to-sales ratio of 4.0x, HIMS is valued at a significant premium to its direct peers but remains below the broader industry average of 5.5x, reflecting embedded growth expectations.

Key Decisions for Investors

• Investors should weigh the company's strong top-line growth drivers and robust full-year guidance against the recent 21.3% share price decline and significant gross margin pressure.
• Closely monitor the company's ability to manage rising product costs, as the 491 bps gross margin contraction in Q2 is a primary risk to future profitability and stock performance.
• Evaluate the execution of the international expansion strategy, including the integration of ZAVA in Europe and the 2026 launch in Canada, as these are key catalysts for justifying the company's growth-oriented valuation.
• Given the stock's 4.0x forward P/S ratio is substantially higher than peers, continued high subscriber growth and increasing revenue per user are critical to sustain its premium valuation.